Biogen Inc.
BIIB - NASDAQ - $193.45 ▲ +%1.08
-
Earnings Thu 30 Jul

Biogen opens the
books on Thursday evening.

13 analysts' median target is $214[FMP target], stock is $193, +10.6% upside potential. After Q1 +21.0% EPS beat[FMP earnings], the stock moved -2.6%.

↓ summary below
Quick Take - in 40 seconds
A-
HOLD Council 2/6 - Moonshot 50

A- = MoonshotScore 50[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $2.4B[FMP est], EPS $3.33[FMP est]. 8 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$3.33 EPS Estimate Last year $1.99 - -39% YoY YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q1 EPS +21.0% beat[FMP] but the stock -2.6% D+1[FMP D+1]. Robin Kramer promised $51.2M CapEx + a sequential decline in Q4 during the Q1 earnings call[Robin Kramer capex transcript].

Watchlist

5 metrics stand out this quarter.

$850 million Investor Focus

Growth Products Q1 Revenue

growth_products_q1_revenue

Growth products generated $850 million in the first quarter of 2026, up 12%.

"And by shifting that to our growth products, I think one of the things you see here on the first slide is that the growth products are now generating $850 million in the first quarter, and that's up 12%."

- Christopher Viehbacher, CEO - Q1 FY26 Earnings Call - April 29, 2026
$151 million Investor Focus

Skyclarys Q1 Revenue

skyclarys_q1_revenue

SKYCLARYS saw sequential global patient demand growth with first quarter 2026 global revenue of $151 million, representing 22% growth year-over-year.

"SKYCLARYS saw sequential global patient demand growth with first quarter 2026 global revenue of $151 million, representing 22% growth year-over-year."

- Robin Kramer, CFO - Q1 FY26 Earnings Call - April 29, 2026
$168 million Investor Focus

Leqembi Market Revenue

leqembi_market_revenue

LEQEMBI market revenue was $168 million for the first quarter of 2026, up 74% year-over-year.

"LEQEMBI market revenue was $168 million for the first quarter of 2026, up 74% year-over-year."

- Robin Kramer, CFO - Q1 FY26 Earnings Call - April 29, 2026
$594 million Investor Focus

Free Cash Flow Q1

free_cash_flow_q1

We generated $594 million of free cash flow in the first quarter of 2026

"We generated $594 million of free cash flow in the first quarter of 2026"

- Robin Kramer, CFO - Q1 FY26 Earnings Call - April 29, 2026
2027 Investor Focus

Apellis Acquisition Accretive

apellis_acquisition_accretive

We do expect the acquisition to be accretive in 2027. And when you look out over the next few years, this materially increases Biogen's EPS outlook.

"So as we look at this, -- we do expect the acquisition to be accretive in 2027. And when you look out over the next few years, this materially increases Biogen's EPS outlook."

- Christopher Viehbacher, CEO - Q1 FY26 Earnings Call - April 29, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 50 / 100

9-pillar methodology. Gross Margin and Cash Runway strong. Revenue Growth weak.

How is it calculated? ->
Revenue Growth0.0Q1 vs Q2: growth negative (-6.3%, contraction)
Gross Margin7.0Q1: very high margin (73.3%, software/cloud territory)
Operating Leverage2.0op margin healthy (16.0%)
Cash Runway10.0FCF very strong ($0.7B, 13.6x CapEx)
R&D Intensity3.0very high R&D (20.1%, margin pressure risk)
Price Momentum7.0RSI 59.4 positive momentum, 50d above
News Sentiment6.0majority buy (55%)
Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +10.6%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 59
Klarman value - target upside +10.6%
Buffett quality - ROE score 3/5
Munger valuation - target upside +10.6%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthStrong
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
59.4 RSI 59.4 positive momentum, 50d above
MACD
+4.80 price above 50d - support positive
50d MA
$185 stock 4.8% above - short-term support
200d MA
$166 stock 16.5% above - long-term support
Volume (10d)
-13% decrease - low participation
Resistance
$214
Analyst median target - upgrade trigger if broken
Current
$193
Pre-earnings position
Support
$141
Invalidation - close below this is a technical breakdown
Pattern
Range
$141-$214 band - earnings breakout/breakdown trigger

Past Performance

Biogen beat expectations in the last 8 quarters.

BEAT
Q2 FY25
$5.47 vs $3.90 est - +3.1%
BEAT
Q3 FY25
$4.81 vs $3.88 est - +3.1%
BEAT
Q4 FY25
$1.99 vs $1.63 est - -3.7%
BEAT
Q1 FY26
$3.57 vs $2.95 est - -2.6%

Q1 (April 29, 2026): EPS $3.57 vs $2.95 est[FMP], +21.0% beat. D+1 movement: -2.6%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $3.23 (no guidance)

Q1: EPS $3.57 vs $2.95 beat[FMP], stock -2.6% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $51.2M[FMP cashflow]. Q1 op margin 16.0%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $3.33 + CapEx discipline
Threshold: EPS > $3.33[FMP est].
Target: Break above median target $214[FMP target]; high target $260[FMP] upper bound.
Scenario B - In-Line
EPS approx $3.33 + CapEx < $51.2M
Threshold: EPS approx $3.33[FMP est], Q4 CapEx < $51.2M[FMP].
Target: Consolidation in the band between current $193[FMP] and median $214[FMP].
Scenario C - Miss
EPS < $3.23 or CapEx >= $51.2M
Threshold: EPS < $3.23[FMP estx0.97].
Target: Current $193 below SMA200 $166[FMP], if rejection continues, $141[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 13 analysts say?

Wall Street Consensus
$214
12-month median target price (+10.6% upside potential)
21
BUY
16
HOLD
1
SELL
Risk Management
$141
Invalidation level - critical support threshold
$185 - 50-day MA (above, +4.8%)
$166 - 200-day MA (above, +16.5%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - BIIB Q4 FY26
A-

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $3.33[FMP], CapEx threshold "below $51.2M"[Robin Kramer]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days BIIB dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 30, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 31, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 13, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 30, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the BIIB earnings preview cover?

This BIIB (BIIB) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in BIIB earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.